Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald J Schuirmann

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|September 26, 2012
Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidateJeanne Fourie Zirkelbach, Andre J Jackson, Yaning Wang, et al.
The AAPS Journal|August 30, 2008
Evaluation of a scaling approach for the bioequivalence of highly variable drugsSam H Haidar, Fairouz Makhlouf, Donald J Schuirmann, et al.
Pharmaceutical Statistics|February 11, 2011
Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'Timothy H Montague, Diane Potvin, Charles E Diliberti, et al.
Pharmaceutical Statistics|August 22, 2007
Sequential design approaches for bioequivalence studies with crossover designsDiane Potvin, Charles E DiLiberti, Walter W Hauck, et al.
The AAPS Journal|April 5, 2015
A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison CriterionWenlei Jiang, Fairouz Makhlouf, Donald J Schuirmann, et al.
Pharmaceutical Statistics|November 6, 2015
Optimal adaptive sequential designs for crossover bioequivalence studiesJialin Xu, Charles Audet, Charles E DiLiberti, et al.
Pharmaceutical Research|September 25, 2007
Bioequivalence approaches for highly variable drugs and drug productsSam H Haidar, Barbara Davit, Mei-Ling Chen, et al.
Pharmaceutical Research|September 24, 2005
Stability, dose uniformity, and palatability of three counterterrorism drugs-human subject and electronic tongue studiesNakissa Sadrieh, James Brower, Lawrence Yu, et al.
The AAPS Journal|September 14, 2012
Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug AdministrationBarbara M Davit, Mei-Ling Chen, Dale P Conner, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|September 26, 2012
Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidateJeanne Fourie Zirkelbach, Andre J Jackson, Yaning Wang, et al.
The AAPS Journal|August 30, 2008
Evaluation of a scaling approach for the bioequivalence of highly variable drugsSam H Haidar, Fairouz Makhlouf, Donald J Schuirmann, et al.
Pharmaceutical Statistics|February 11, 2011
Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'Timothy H Montague, Diane Potvin, Charles E Diliberti, et al.
Pharmaceutical Statistics|August 22, 2007
Sequential design approaches for bioequivalence studies with crossover designsDiane Potvin, Charles E DiLiberti, Walter W Hauck, et al.
The AAPS Journal|April 5, 2015
A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison CriterionWenlei Jiang, Fairouz Makhlouf, Donald J Schuirmann, et al.
Pharmaceutical Statistics|November 6, 2015
Optimal adaptive sequential designs for crossover bioequivalence studiesJialin Xu, Charles Audet, Charles E DiLiberti, et al.
Pharmaceutical Research|September 25, 2007
Bioequivalence approaches for highly variable drugs and drug productsSam H Haidar, Barbara Davit, Mei-Ling Chen, et al.
Pharmaceutical Research|September 24, 2005
Stability, dose uniformity, and palatability of three counterterrorism drugs-human subject and electronic tongue studiesNakissa Sadrieh, James Brower, Lawrence Yu, et al.
The AAPS Journal|September 14, 2012
Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug AdministrationBarbara M Davit, Mei-Ling Chen, Dale P Conner, et al.
Pageof 1